Artelo Biosciences (Artelo Biosciences) Pre-Tax Income : $-9.60 Mil (TTM As of Mar. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Artelo Biosciences Pre-Tax Income?

Pretax income is the income that a company earns before paying income taxes. Artelo Biosciences's pretax income for the three months ended in Mar. 2024 was $-2.48 Mil. Its pretax income for the trailing twelve months (TTM) ended in Mar. 2024 was $-9.60 Mil. Artelo Biosciences's pretax margin was %.

Artelo Biosciences Pre-Tax Income Historical Data

The historical data trend for Artelo Biosciences's Pre-Tax Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Artelo Biosciences Pre-Tax Income Chart

Artelo Biosciences Annual Data

Trend

Aug14

Aug15

Aug16

Aug17

Aug18

Aug19

Aug20

Aug21

Dec22

Dec23

Pre-Tax Income

Get a 7-Day Free Trial

-2.17

-4.66

-7.44

-10.08

-9.29

Artelo Biosciences Quarterly Data
	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Pre-Tax Income	Get a 7-Day Free Trial															-2.17	-1.60	-2.45	-3.07	-2.48

Competitive Comparison of Artelo Biosciences's Pre-Tax Income

For the Biotechnology subindustry, Artelo Biosciences's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Artelo Biosciences's Pre-Tax Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Artelo Biosciences's Pre-Tax Income distribution charts can be found below:

* The bar in red indicates where Artelo Biosciences's Pre-Tax Income falls into.

Artelo Biosciences Pre-Tax Income Calculation

This is the income that a company earns before paying income taxes.

Artelo Biosciences's Pretax Income for the fiscal year that ended in Dec. 2023 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-9.93	+	0.641	+	0	+	0	+	0
	=	-9.29

Artelo Biosciences's Pretax Income for the quarter that ended in Mar. 2024 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-2.589	+	0.106	+	0	+	0	+	0
	=	-2.48

Pre-Tax Income for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-9.60 Mil.

Artelo Biosciences (NAS:ARTLW) Pre-Tax Income Explanation

Artelo Biosciences's Pretax Margin for the quarter that ended in Mar. 2024 is calculated as

Pretax Margin	=	Pretax Income	/	Revenue
	=	-2.483	/	0
	=	%

Artelo Biosciences Pre-Tax Income Related Terms

Thank you for viewing the detailed overview of Artelo Biosciences's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Artelo Biosciences (Artelo Biosciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Artelo Biosciences Inc (NAS:ARTLW) » Definitions » Pre-Tax Income

Comparable Companies

Traded in Other Exchanges

ARTL:USA

Address

505 Lomas Santa Fe, Suite 160, Solana Beach, CA, USA, 92075

Website

https://www.artelobio.com

Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors and neurotransmitters that form a biochemical communication network in body. It is focused on discovering, licensing, developing and commercializing treatments that control endocannabinoid system. The company pursues technologies and programs that offer proprietary approaches to cannabinoid-based therapies, also those derived from the cannabis plant and synthetic cannabinoids, as well as new chemical entities and compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare and orphan disease.